Eric Jonasch, MD
Board Member, Medical Advisory Board Chair, United States
Dr Eric Jonasch is a distinguished Medical Oncologist with over 20 years of experience in the treatment of kidney cancer and von Hippel-Lindau disease. A Board member of the IKCC since 2016, he currently serves as the Chair of the Medical Advisory Board, a role in which he shapes global strategies to improve kidney cancer care and supports IKCC’s commitment to evidence-based activities and advocacy.
Dr Jonasch is Professor in the Department of Genitourinary Medical Oncology, Division of Cancer Center at the University of Texas MD Anderson Cancer Center in Houston, United States, Director of the VHL Clinical Center at the MD Anderson Cancer Center, and co-Director of the MD Anderson Kidney Cancer Research Program. Through his decades-long research and involvement in the development of therapeutic agents for kidney cancer, Dr. Jonasch has contributed significantly to treatment advancements. He has also served as Vice-Chair of the National Comprehensive Cancer Network (NCCN) Kidney Cancer Guidelines for over 10 years, providing expert guidance on treatment protocols.
Having treated patients with kidney cancer for the length of his medical career, Dr Jonasch is committed to improving outcomes for patients worldwide. Through his role on the IKCC Board, he aims to further the Coalition’s mission to combat kidney cancer on a global scale, focusing on the dissemination of best practices for the management of this devastating disease.
Term
First term: 2017 – 2020
Second term: 2020 – 2023
Third term: 2023 – 2026*
*In April 2023, motion passed indicating Chair of the Medical Advisory Board should become an Ex Officio position within the main IKCC Board of Directors.